| AI | Artificial intelligence |
| APC | Antigen-presenting cell |
| CR | Complete response |
| DC | Dendritic cell |
| DCR | Disease control rate |
| DoR | Duration of response |
| ELISpot | Enzyme-linked immunospot assay |
| GM-CSF | Granulocyte-macrophage colony-stimulating factor |
| ICI | Immune checkpoint inhibitor |
| LAG-3 | Lymphocyte-activation gene 3 |
| NED | No evidence of disease |
| NSCLC | Non-small cell lung cancer |
| ORR | Objective response rate |
| OS | Overall survival |
| PD | Progressive disease |
| PD-1 | Programmed cell death protein 1 |
| PFS | Progression-free survival |
| PR | Partial response |
| SD | Stable disease |
| STING | Stimulator of interferon gene |
| TIM-3 | T-cell immunoglobulin and mucin-domain containing 3 |
| TIGIT | T-cell immunoreceptor with Ig and ITIM domains |
| TLR | Toll-like receptor |
| TME | Tumor microenvironment |
| TNBC | Triple-negative breast cancer |